Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Globus Medical Inc. Class A Common Stock (GMED) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Globus Medical Inc. Class A Common StockTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Globus Medical Inc. Class A Common Stock vs Oxford Lane Capital Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Oxford Lane Capital Corp trades at $8.37 (market cap $806.30M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 12.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 29.18% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Oxford Lane Capital Corp for 51 Days on average.

GMEDOXLC
Market Cap
$10.25B$806.30M
Volume
1,059,5281,199,574
Sector
HealthFinancials
52-Week High
$96.82$16.02
52-Week Low
$58.33$8.15
Typical Hold Time
0 Days51 Days
Enterprise Value
$9.76B$1.20B
Dividend Yield
—29.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Globus Medical Inc. Class A Common Stock

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Oxford Lane Capital Corp

OXLC trades at $8.34, down 3.02% on the day, with a bearish technical outlook and weak earnings performance. Recent quarters show significant EPS misses, including a -$6.23 actual versus $2.26 expected in Q1 2026. The company maintains a high dividend payout of $0.20 monthly, but negative ROE and ROA highlight profitability challenges. Net asset value updates indicate substantial unrealized losses, with revenue turning negative in 2026.

The outlook is cautious due to deteriorating fundamentals and high payout ratios exceeding sustainable levels. Investment opportunities exist for yield-seeking investors attracted to the deep discount to NAV, but risks include persistent earnings volatility, reliance on financing for cash flow, and competitive pressures in the CLO space. Analyst sentiment is mixed, with 50% buy ratings offset by bearish technical signals.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GMED
100% Buy0% Sell
Avg holding period · 0 Days
OXLC
100% Buy0% Sell
Avg holding period · 51 Days

Top news

Latest headlines on both assets

About Globus Medical Inc. Class A Common Stock

Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.

Read more on GMED →

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC →